Composition comprising aptamer as active ingredient for treatment and prevention of degenerative brain disease

Inventor: In Sik Son (Seongnam-si, KR)

Assignee: NEXMOS Co., Ltd.

C12N15/115 A61K31/375 A61K31/713 A61P25/16

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,227,747
App. No.: 17/292,710
Granted: Feb 18, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to a composition for treating and preventing degenerative brain diseases comprising a complex of vitamin C and an aptamer binding to the vitamin C as an active ingredient, and the composition of the present invention has improved and therapeutic effects in a Parkinson's disease experimental model and so the composition of the present invention can be used as medicines and health functional foods for patients with degenerative brain diseases including Parkinson's disease.

Claims (5)

1. A composition for the treatment and prevention of degenerative brain diseases comprising an aptamer consisting of the nucleotide sequence of SEQ ID: 1 and vitamin C.

2. The composition for treating and preventing degenerative brain diseases according to claim 1 , wherein the mixing ratio of vitamin C and aptamer is in the range of 10:1 to 500:1 by weight.

3. The composition for treating and preventing degenerative brain diseases according to claim 1 , wherein the composition has a neuronal protective effect.

4. The composition for treating and preventing degenerative brain diseases according to claim 1 , wherein the degenerative brain disease is selected from the group consisting of stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and amyotrophic lateral sclerosis.

5. The composition for treating and preventing degenerative brain disease according to claim 4 , wherein the degenerative brain disease is Parkinson's disease.

Priority Claims (2)

KR 10-2018-0140074 · Nov 14, 2018 · national

KR 10-2019-0055758 · May 13, 2019 · national

Continuity (1)

Related Publication 20220002729A1 · Jan 6, 2022

References Cited (11)

US 10201489B2 · Son · 2019 [cited by examiner]

US 10655131B2 · Son · 2020 [cited by examiner]

US 20190078094A1 · Son · 2019 [cited by applicant]

EP 3530260 · 2019 [cited by applicant]

EP 3530260A1 · 2019 [cited by examiner]

KR 1020190050372 · 2019 [cited by applicant]

WO 2018074763 · 2018 [cited by applicant]

Minkyung Song et al., “Nuroprotective effect of Aptamin-C in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Induced Parkinson's disease mice model”, IBRO Reports, vol. 6 p. S96 P02.21, Sep. 2019. [cited by applicant]

Adriana Covarrubias-Pinto et al., “Old Things New View: Assorbic Acid Protects the Brain in Neurodegenerative Disorders”, international journal of molecular sciences, vol. 16, pp. 28194-28217, 2015. [cited by applicant]

Morgana Moretti et al.,, “Preventive and therapeutic potential of ascorbic acid in neurodegenerative diseases”, CNS Neuroscience & Therapeutics, vol. 23, pp. 921-929, 2017. [cited by applicant]

Office Action for Japan Patent Application No. 2021-526288, dated Jun. 21, 2022. [cited by applicant]